Why the pharmaceutical industry is interested in research on care pathways

Abstract

The pharmaceutical company Pfizer is supporting an international study on care pathways, being carried out by the European Pathway Association. Over the last few years, this pharmaceutical company has spent a substantial amount of money to make this study on care pathways possible. This international research as well as the contribution of Pfizer Belgium, also counts on the support of Pfizer Ireland, Portugal and Italy. Pfizer Belgium directors Kris Westelinck (Managing Director) and Peter Menu (Director Public Affairs and Policy) elucidate their plans, together with KU Leuven Professor Arthur Vleugels during an interview by Dirk Blyweert (independent journalist).